Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $189 from $178 and keeps an Outperform rating on the shares. The firm ...

Barclays raised their target price on Quest Diagnostics from $168.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Friday, January 31st. Jefferies Financial ...

Baird raised the firm’s price target on Quest Diagnostics (DGX) to $191 from $190 and keeps an Outperform rating on the shares. The firm updated its model following its Investor Day. Published ...

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the ...

In addition to the price target update, Mizuho is maintaining its adjusted earnings per share (EPS) estimates for 2025 and ...

Quest Diagnostics Inc. closed 8.28% below its 52-week high of $178.87, which the company reached on March 10th.

Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...

Grail shares are trading higher Wednesday after the company announced a new collaboration with Quest Diagnostics aimed at improving provider access to its Galleri multi-cancer early detection test.

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS ...

likely played influential roles in the 11.57% stock price increase over the past quarter. The broader... Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced ...